CA2569512C - Recombinase polymerase amplification - Google Patents
Recombinase polymerase amplification Download PDFInfo
- Publication number
- CA2569512C CA2569512C CA2569512A CA2569512A CA2569512C CA 2569512 C CA2569512 C CA 2569512C CA 2569512 A CA2569512 A CA 2569512A CA 2569512 A CA2569512 A CA 2569512A CA 2569512 C CA2569512 C CA 2569512C
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- primer
- dna
- polymerase
- recombinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000018120 Recombinases Human genes 0.000 title claims abstract description 256
- 108010091086 Recombinases Proteins 0.000 title claims abstract description 256
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 190
- 230000003321 amplification Effects 0.000 title claims abstract description 189
- 238000006243 chemical reaction Methods 0.000 claims abstract description 333
- 238000000034 method Methods 0.000 claims abstract description 321
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 262
- 108020004414 DNA Proteins 0.000 claims abstract description 148
- 102000053602 DNA Human genes 0.000 claims abstract description 127
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 104
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 100
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims abstract description 57
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims abstract description 57
- 239000000523 sample Substances 0.000 claims abstract description 53
- 102000004190 Enzymes Human genes 0.000 claims abstract description 51
- 108090000790 Enzymes Proteins 0.000 claims abstract description 51
- 238000012544 monitoring process Methods 0.000 claims abstract description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 247
- 102000039446 nucleic acids Human genes 0.000 claims description 240
- 108020004707 nucleic acids Proteins 0.000 claims description 240
- 230000008569 process Effects 0.000 claims description 192
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 169
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 168
- 101800001466 Envelope glycoprotein E1 Proteins 0.000 claims description 163
- 230000000694 effects Effects 0.000 claims description 152
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 137
- 241000588724 Escherichia coli Species 0.000 claims description 105
- 230000015572 biosynthetic process Effects 0.000 claims description 98
- 108010055016 Rec A Recombinases Proteins 0.000 claims description 89
- 102000001218 Rec A Recombinases Human genes 0.000 claims description 89
- 238000003786 synthesis reaction Methods 0.000 claims description 76
- 239000003795 chemical substances by application Substances 0.000 claims description 75
- 101150079601 recA gene Proteins 0.000 claims description 69
- 102000011931 Nucleoproteins Human genes 0.000 claims description 68
- 108010061100 Nucleoproteins Proteins 0.000 claims description 68
- 229920001223 polyethylene glycol Polymers 0.000 claims description 66
- 230000000295 complement effect Effects 0.000 claims description 55
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 54
- 239000003153 chemical reaction reagent Substances 0.000 claims description 52
- 230000010076 replication Effects 0.000 claims description 51
- 239000002202 Polyethylene glycol Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 41
- 101100048967 Enterobacteria phage T4 uvsY gene Proteins 0.000 claims description 39
- 239000000243 solution Substances 0.000 claims description 39
- 230000005012 migration Effects 0.000 claims description 38
- 238000013508 migration Methods 0.000 claims description 38
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 claims description 37
- 238000011068 loading method Methods 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 35
- 108060004795 Methyltransferase Proteins 0.000 claims description 32
- 238000009396 hybridization Methods 0.000 claims description 32
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 31
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 31
- 230000006820 DNA synthesis Effects 0.000 claims description 30
- 101710176276 SSB protein Proteins 0.000 claims description 30
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 claims description 30
- 230000027455 binding Effects 0.000 claims description 29
- 238000002844 melting Methods 0.000 claims description 28
- 101710116602 DNA-Binding protein G5P Proteins 0.000 claims description 27
- 101710162453 Replication factor A Proteins 0.000 claims description 27
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 claims description 27
- 230000008018 melting Effects 0.000 claims description 27
- 108060002716 Exonuclease Proteins 0.000 claims description 26
- 102000013165 exonuclease Human genes 0.000 claims description 26
- 230000004544 DNA amplification Effects 0.000 claims description 23
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims description 22
- -1 nucleoside triphosphate Chemical class 0.000 claims description 22
- 108010025076 Holoenzymes Proteins 0.000 claims description 21
- 108010092681 DNA Primase Proteins 0.000 claims description 20
- 102000016559 DNA Primase Human genes 0.000 claims description 20
- 239000000872 buffer Substances 0.000 claims description 18
- 230000008929 regeneration Effects 0.000 claims description 17
- 238000011069 regeneration method Methods 0.000 claims description 17
- 239000000539 dimer Substances 0.000 claims description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 14
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 12
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 12
- 239000001226 triphosphate Substances 0.000 claims description 12
- 235000011178 triphosphate Nutrition 0.000 claims description 12
- 102000004420 Creatine Kinase Human genes 0.000 claims description 11
- 108010042126 Creatine kinase Proteins 0.000 claims description 11
- 241000549435 Pria Species 0.000 claims description 11
- 238000011534 incubation Methods 0.000 claims description 11
- 229950007002 phosphocreatine Drugs 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 11
- 101710163270 Nuclease Proteins 0.000 claims description 10
- 239000008351 acetate buffer Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 108091008146 restriction endonucleases Proteins 0.000 claims description 10
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 claims description 10
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 9
- 235000011180 diphosphates Nutrition 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 244000063299 Bacillus subtilis Species 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 8
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 8
- 239000002532 enzyme inhibitor Substances 0.000 claims description 8
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 239000002777 nucleoside Substances 0.000 claims description 8
- 244000052769 pathogen Species 0.000 claims description 8
- 101150033993 recR gene Proteins 0.000 claims description 8
- 108010061982 DNA Ligases Proteins 0.000 claims description 7
- 102000012410 DNA Ligases Human genes 0.000 claims description 7
- 108010071146 DNA Polymerase III Proteins 0.000 claims description 7
- 102000007528 DNA Polymerase III Human genes 0.000 claims description 7
- 108700020796 Oncogene Proteins 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 claims description 6
- 101710183280 Topoisomerase Proteins 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 239000011654 magnesium acetate Substances 0.000 claims description 6
- 229940069446 magnesium acetate Drugs 0.000 claims description 6
- 235000011285 magnesium acetate Nutrition 0.000 claims description 6
- 235000011056 potassium acetate Nutrition 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 claims description 5
- 101000990000 Enterobacteria phage T4 Sliding clamp Proteins 0.000 claims description 5
- 102000004150 Flap endonucleases Human genes 0.000 claims description 5
- 108090000652 Flap endonucleases Proteins 0.000 claims description 5
- 241000193385 Geobacillus stearothermophilus Species 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 108050006400 Cyclin Proteins 0.000 claims description 4
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 4
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 claims description 4
- 101710159527 Maturation protein A Proteins 0.000 claims description 4
- 101710091157 Maturation protein A2 Proteins 0.000 claims description 4
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 101150103919 recO gene Proteins 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- 108010063113 DNA Polymerase II Proteins 0.000 claims description 3
- 102000010567 DNA Polymerase II Human genes 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 108010006296 DnaB Helicases Proteins 0.000 claims description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 claims description 3
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 102000009609 Pyrophosphatases Human genes 0.000 claims description 3
- 108010009413 Pyrophosphatases Proteins 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 208000016361 genetic disease Diseases 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 238000010791 quenching Methods 0.000 claims description 3
- 230000000171 quenching effect Effects 0.000 claims description 3
- 101710197907 rDNA transcriptional regulator pol5 Proteins 0.000 claims description 3
- 108010068698 spleen exonuclease Proteins 0.000 claims description 3
- 101100443914 Enterobacteria phage T4 43 gene Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims description 2
- 102100031780 Endonuclease Human genes 0.000 claims 5
- 108010042407 Endonucleases Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims 2
- 229920001917 Ficoll Polymers 0.000 claims 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 2
- 239000002751 oligonucleotide probe Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 101000913035 Homo sapiens Flap endonuclease 1 Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 108090000944 RNA Helicases Proteins 0.000 claims 1
- 102000004409 RNA Helicases Human genes 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 108091028733 RNTP Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 150000001484 arginines Chemical class 0.000 claims 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 1
- 102000055860 human FEN1 Human genes 0.000 claims 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 238000005215 recombination Methods 0.000 abstract description 82
- 230000006798 recombination Effects 0.000 abstract description 82
- 238000013459 approach Methods 0.000 abstract description 49
- 230000008901 benefit Effects 0.000 abstract description 22
- 230000037452 priming Effects 0.000 abstract description 16
- 238000001502 gel electrophoresis Methods 0.000 abstract description 7
- 238000011109 contamination Methods 0.000 abstract description 4
- 239000013615 primer Substances 0.000 description 296
- 239000000047 product Substances 0.000 description 98
- 235000018102 proteins Nutrition 0.000 description 93
- 108020004682 Single-Stranded DNA Proteins 0.000 description 71
- 239000000306 component Substances 0.000 description 71
- 230000009545 invasion Effects 0.000 description 68
- 238000003752 polymerase chain reaction Methods 0.000 description 50
- 238000002474 experimental method Methods 0.000 description 43
- 230000008685 targeting Effects 0.000 description 43
- 229940088598 enzyme Drugs 0.000 description 42
- 239000000543 intermediate Substances 0.000 description 39
- 239000002773 nucleotide Substances 0.000 description 37
- 238000006460 hydrolysis reaction Methods 0.000 description 36
- 125000003729 nucleotide group Chemical group 0.000 description 35
- 230000007062 hydrolysis Effects 0.000 description 34
- 230000006870 function Effects 0.000 description 31
- 230000006399 behavior Effects 0.000 description 30
- 239000012071 phase Substances 0.000 description 30
- 108091093088 Amplicon Proteins 0.000 description 26
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 24
- 238000001514 detection method Methods 0.000 description 23
- 230000035945 sensitivity Effects 0.000 description 23
- 230000003993 interaction Effects 0.000 description 22
- 108700014590 single-stranded DNA binding proteins Proteins 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 19
- 238000006073 displacement reaction Methods 0.000 description 17
- 235000000346 sugar Nutrition 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 230000000977 initiatory effect Effects 0.000 description 16
- 230000002441 reversible effect Effects 0.000 description 16
- 238000009825 accumulation Methods 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 15
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 14
- 229910052737 gold Inorganic materials 0.000 description 14
- 239000010931 gold Substances 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 238000013461 design Methods 0.000 description 13
- 102000014914 Carrier Proteins Human genes 0.000 description 12
- 108091008324 binding proteins Proteins 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 239000000975 dye Substances 0.000 description 12
- 241000701533 Escherichia virus T4 Species 0.000 description 11
- 239000013616 RNA primer Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000010494 dissociation reaction Methods 0.000 description 11
- 230000005593 dissociations Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 239000003155 DNA primer Substances 0.000 description 10
- 239000007795 chemical reaction product Substances 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 230000004568 DNA-binding Effects 0.000 description 9
- 238000000137 annealing Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000008093 supporting effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101710135281 DNA polymerase III PolC-type Proteins 0.000 description 5
- 101000749445 Enterobacteria phage T4 Recombination and repair protein Proteins 0.000 description 5
- 108091064358 Holliday junction Proteins 0.000 description 5
- 102000039011 Holliday junction Human genes 0.000 description 5
- UOLVQBSMMHANLG-XZNUSECASA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[1-(2-nitrophenyl)ethoxy]phosphoryl] hydrogen phosphate Chemical compound C([C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C2=NC=NC(N)=C2N=C1)O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC(C)C1=CC=CC=C1[N+]([O-])=O UOLVQBSMMHANLG-XZNUSECASA-N 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000001351 cycling effect Effects 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 102220491783 High mobility group protein B1_K3A_mutation Human genes 0.000 description 4
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 4
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000737 periodic effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012772 sequence design Methods 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000621107 Enterobacteria phage N4 Probable portal protein Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000285023 Formosa Species 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 102000002933 Thioredoxin Human genes 0.000 description 3
- 230000002730 additional effect Effects 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- DSSYKIVIOFKYAU-UHFFFAOYSA-N camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000001046 green dye Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000009738 saturating Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 229940094937 thioredoxin Drugs 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 101800000112 Acidic peptide Proteins 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 108090000133 DNA helicases Proteins 0.000 description 2
- 102000003844 DNA helicases Human genes 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 101000829157 Enterobacteria phage T4 Single-stranded DNA-binding protein Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 101000669895 Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 / JCM 10044 / NBRC 100330 / Delta H) Replication factor A Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000425347 Phyla <beetle> Species 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 208000014633 Retinitis punctata albescens Diseases 0.000 description 2
- 101710082933 Single-strand DNA-binding protein Proteins 0.000 description 2
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008358 core component Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000013383 initial experiment Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 125000001921 locked nucleotide group Chemical group 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 238000006303 photolysis reaction Methods 0.000 description 2
- 230000015843 photosynthesis, light reaction Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010223 real-time analysis Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 108091011108 ATP binding proteins Proteins 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000207207 Aquifex pyrophilus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101900090047 Bacillus subtilis DNA polymerase I Proteins 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010001132 DNA Polymerase beta Proteins 0.000 description 1
- 102000001996 DNA Polymerase beta Human genes 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 101710159156 DNA polymerase IV Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000702224 Enterobacteria phage M13 Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 101000906736 Escherichia phage Mu DNA circularization protein N Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101001057037 Gallus gallus Adenylate kinase isoenzyme 1 Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000002769 Morchella esculenta Species 0.000 description 1
- 235000002779 Morchella esculenta Nutrition 0.000 description 1
- 101100010166 Mus musculus Dok3 gene Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000243981 Onchocerca Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000205223 Pyrobaculum islandicum Species 0.000 description 1
- 241000205156 Pyrococcus furiosus Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108700018273 Rad30 Proteins 0.000 description 1
- 108091036333 Rapid DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000032825 Ring chromosome 2 syndrome Diseases 0.000 description 1
- 241001466077 Salina Species 0.000 description 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000589196 Sinorhizobium meliloti Species 0.000 description 1
- 101710119335 Sliding-clamp-loader large subunit Proteins 0.000 description 1
- 101710087759 Sliding-clamp-loader small subunit Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 101000764570 Streptomyces phage phiC31 Probable tape measure protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710194518 T4 protein Proteins 0.000 description 1
- 241001235254 Thermococcus kodakarensis Species 0.000 description 1
- 241000204666 Thermotoga maritima Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 244000301083 Ustilago maydis Species 0.000 description 1
- 235000015919 Ustilago maydis Nutrition 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000009146 cooperative binding Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 230000008846 dynamic interplay Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 108060006184 phycobiliprotein Proteins 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 101150002589 recF gene Proteins 0.000 description 1
- 101150066870 recG gene Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 101150061752 ruvA gene Proteins 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2921988A CA2921988C (en) | 2004-06-01 | 2005-04-11 | Recombinase polymerase amplification |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57616204P | 2004-06-01 | 2004-06-01 | |
| US57614804P | 2004-06-01 | 2004-06-01 | |
| US60/576,148 | 2004-06-01 | ||
| US60/576,162 | 2004-06-01 | ||
| US10/931,916 | 2004-09-01 | ||
| US10/931,916 US7399590B2 (en) | 2002-02-21 | 2004-09-01 | Recombinase polymerase amplification |
| US62229104P | 2004-10-26 | 2004-10-26 | |
| US60/622,291 | 2004-10-26 | ||
| US63274604P | 2004-12-02 | 2004-12-02 | |
| US60/632,746 | 2004-12-02 | ||
| PCT/IB2005/001560 WO2005118853A2 (en) | 2004-06-01 | 2005-04-11 | Recombinase polymerase amplification |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2921988A Division CA2921988C (en) | 2004-06-01 | 2005-04-11 | Recombinase polymerase amplification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2569512A1 CA2569512A1 (en) | 2005-12-15 |
| CA2569512C true CA2569512C (en) | 2016-05-31 |
Family
ID=35463460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2569512A Expired - Lifetime CA2569512C (en) | 2004-06-01 | 2005-04-11 | Recombinase polymerase amplification |
Country Status (6)
| Country | Link |
|---|---|
| EP (4) | EP2336361B1 (enExample) |
| JP (4) | JP5026958B2 (enExample) |
| AU (1) | AU2005250233B2 (enExample) |
| CA (1) | CA2569512C (enExample) |
| ES (2) | ES2425354T3 (enExample) |
| WO (1) | WO2005118853A2 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1141275B1 (en) | 1999-01-05 | 2009-08-12 | Trustees Of Boston University | Improved nucleic acid cloning |
| US7435562B2 (en) | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
| AU2003215391B2 (en) * | 2002-02-21 | 2007-05-24 | Abbott Diagnostics Scarborough, Inc. | Recombinase Polymerase Amplification |
| US7399590B2 (en) | 2002-02-21 | 2008-07-15 | Asm Scientific, Inc. | Recombinase polymerase amplification |
| US8030000B2 (en) | 2002-02-21 | 2011-10-04 | Alere San Diego, Inc. | Recombinase polymerase amplification |
| AU2005250239A1 (en) | 2004-06-02 | 2005-12-15 | Alere San Diego, Inc. | 2'-nitrobenzyl-modified ribonucleotides |
| CA2590245A1 (en) | 2004-11-11 | 2006-05-18 | Modular Genetics, Inc. | Ladder assembly and system for generating diversity |
| CA2616241C (en) | 2005-07-25 | 2012-02-07 | Asm Scientific, Inc. | Methods for multiplexing recombinase polymerase amplification |
| CA2650993C (en) | 2006-05-04 | 2015-06-16 | Asm Scientific, Inc. | Recombinase polymerase amplification |
| AU2016204451B2 (en) * | 2006-05-04 | 2017-05-11 | Abbott Diagnostics Scarborough, Inc. | Recombinase Polymerase Amplification |
| US7501254B2 (en) | 2006-07-20 | 2009-03-10 | Ghc Technologies, Inc. | Methods and compositions for amplification and capture of nucleic acid sequences |
| JP4918409B2 (ja) | 2006-07-26 | 2012-04-18 | 西川ゴム工業株式会社 | 核酸配列の増幅方法 |
| DE102006054562A1 (de) * | 2006-11-20 | 2008-05-21 | Bayer Healthcare Ag | Verfahren zum Nachweis von Pyrophosphat mit Biolumineszenz Detektion |
| US9689031B2 (en) | 2007-07-14 | 2017-06-27 | Ionian Technologies, Inc. | Nicking and extension amplification reaction for the exponential amplification of nucleic acids |
| CN102119225B (zh) * | 2008-06-11 | 2015-04-08 | 基因排列技术有限公司 | 等温核酸扩增 |
| US9309557B2 (en) | 2010-12-17 | 2016-04-12 | Life Technologies Corporation | Nucleic acid amplification |
| US9334531B2 (en) | 2010-12-17 | 2016-05-10 | Life Technologies Corporation | Nucleic acid amplification |
| WO2010135310A1 (en) | 2009-05-20 | 2010-11-25 | Biosite Incorporated | Dna glycosylase/lyase and ap endonuclease substrates |
| EP2438196B1 (en) * | 2009-06-05 | 2016-12-21 | Alere San Diego, Inc. | Recombinase polymerase amplification reagents and kits |
| CN107739750A (zh) * | 2009-09-25 | 2018-02-27 | 艾利尔圣迭戈公司 | 粗基质中的核酸的检测 |
| US9399217B2 (en) | 2010-10-04 | 2016-07-26 | Genapsys, Inc. | Chamber free nanoreactor system |
| GB2499340B (en) | 2010-10-04 | 2015-10-28 | Genapsys Inc | Methods for sequencing nucleic acids |
| US9184099B2 (en) | 2010-10-04 | 2015-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Biosensor devices, systems and methods therefor |
| CN110079588B (zh) | 2010-12-17 | 2024-03-15 | 生命技术公司 | 用于核酸扩增的方法、组合物、系统、仪器和试剂盒 |
| JP5961247B2 (ja) | 2011-04-07 | 2016-08-02 | アリーア サン ディエゴ， インコーポレイテッド | リコンビナーゼポリメラーゼ増幅混合物のモニタリング |
| US9926596B2 (en) | 2011-05-27 | 2018-03-27 | Genapsys, Inc. | Systems and methods for genetic and biological analysis |
| US9352312B2 (en) | 2011-09-23 | 2016-05-31 | Alere Switzerland Gmbh | System and apparatus for reactions |
| WO2013082619A1 (en) | 2011-12-01 | 2013-06-06 | Genapsys, Inc. | Systems and methods for high efficiency electronic sequencing and detection |
| JP5958034B2 (ja) * | 2012-04-11 | 2016-07-27 | 富士レビオ株式会社 | 分子ビーコン型プローブを用いた標的核酸の検出方法 |
| KR20150011359A (ko) | 2012-04-19 | 2015-01-30 | 라이프 테크놀로지스 코포레이션 | 디지털 pcr을 수행하는 방법 |
| WO2014007289A1 (ja) * | 2012-07-05 | 2014-01-09 | 日本碍子株式会社 | 核酸クロマトグラフィー法、核酸クロマトグラフィー用組成物及びこれを含むキット |
| CN102816756B (zh) * | 2012-09-07 | 2014-04-16 | 江苏奇天基因生物科技有限公司 | 等温核酸扩增反应试剂及等温核酸扩增方法 |
| CA2896879C (en) | 2013-03-15 | 2020-09-22 | Genapsys, Inc. | Systems and methods for biological analysis |
| JP5904153B2 (ja) * | 2013-03-29 | 2016-04-13 | ソニー株式会社 | 核酸増幅反応用試料の調製方法、核酸増幅方法、固相状核酸増幅反応用試薬及びマイクロチップ |
| CA2912307C (en) * | 2013-06-11 | 2022-01-11 | Biocartis Nv | Biomolecule drying process for long-term storage |
| EP3792921A1 (en) | 2013-12-11 | 2021-03-17 | Genapsys, Inc. | Systems and methods for biological analysis and computation |
| WO2015161054A2 (en) | 2014-04-18 | 2015-10-22 | Genapsys, Inc. | Methods and systems for nucleic acid amplification |
| EP2966177A1 (en) | 2014-07-09 | 2016-01-13 | Vetgenomics, S.L. | Methods for detecting target DNA sequences |
| CN104232622B (zh) | 2014-09-24 | 2016-09-14 | 中国人民解放军疾病预防控制所 | 一种用聚合酶螺旋反应恒温扩增核酸的方法及其应用 |
| US20180148716A1 (en) * | 2015-03-31 | 2018-05-31 | Qiagen Gmbh | Efficiency improving ligation methods |
| GB201519565D0 (en) | 2015-11-05 | 2015-12-23 | Alere San Diego Inc | Sample preparation device |
| CN114645100A (zh) * | 2016-01-29 | 2022-06-21 | 中国动物卫生与流行病学中心 | 一种检测h7亚型禽流感病毒的引物对及其引用、检测h7亚型禽流感病毒的方法 |
| ES2835101T3 (es) * | 2016-02-10 | 2021-06-21 | Univ Michigan Regents | Detección de ácidos nucleicos |
| CN105543402B (zh) * | 2016-03-02 | 2019-07-02 | 刘国宪 | 等温核酸扩增反应试剂及等温核酸扩增方法 |
| AU2017228401B2 (en) | 2016-03-04 | 2023-07-27 | Abbott Diagnostics Scarborough, Inc. | Automated nested recombinase polymerase amplification |
| US11299777B2 (en) | 2016-04-04 | 2022-04-12 | Nat Diagnostics, Inc. | Isothermal amplification components and processes |
| US9617587B1 (en) | 2016-04-04 | 2017-04-11 | Nat Diagnostics, Inc. | Isothermal amplification components and processes |
| DE102016108115B4 (de) | 2016-05-02 | 2019-05-09 | Agilent Technologies, Inc. - A Delaware Corporation - | Probenpuffer mit niedermolekularem Farbstoffstabilisator für Gelelektrophorese |
| GB201611469D0 (en) | 2016-06-30 | 2016-08-17 | Lumiradx Tech Ltd | Improvements in or relating to nucleic acid amplification processes |
| CN109790575A (zh) | 2016-07-20 | 2019-05-21 | 吉纳普赛斯股份有限公司 | 用于核酸测序的系统和方法 |
| CN106399590B (zh) * | 2016-10-31 | 2019-12-13 | 中国人民解放军军事医学科学院微生物流行病研究所 | 呼吸道感染相关腺病毒的通用型核酸等温检测试剂 |
| AU2018227436A1 (en) * | 2017-02-28 | 2019-09-12 | Abbott Diagnostics Scarborough, Inc. | Microfluidic devices and related methods |
| CA3055565A1 (en) | 2017-03-08 | 2018-09-13 | The Regents Of The University Of Michigan | Analyte detection |
| EP3684951A4 (en) | 2017-09-21 | 2021-06-16 | Genapsys, Inc. | NUCLEIC ACID SEQUENCING SYSTEMS AND METHODS |
| CN108130369A (zh) * | 2017-12-29 | 2018-06-08 | 博迪泰（厦门）生物科技有限公司 | 一种检测乳牛短脊椎综合症的引物、试剂盒及检测方法 |
| GB2569965A (en) | 2018-01-04 | 2019-07-10 | Lumiradx Uk Ltd | Improvements in or relating to amplification of nucleic acids |
| JP7386167B2 (ja) * | 2018-01-24 | 2023-11-24 | ペルキネルマー ヘルス サイエンシーズ， インコーポレイテッド | 分離によるマイクロ流体チップ内の核酸の精製 |
| CN112292460A (zh) | 2018-06-12 | 2021-01-29 | 主基因有限公司 | 核酸扩增方法 |
| DE102018222357A1 (de) * | 2018-12-19 | 2020-06-25 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | In-vitro-Verfahren zum Nachweis von mindestens einer Nukleinsäure, die sich bei einem Lebewesen im Vollblut außerhalb der Blutzellen befindet und Vorrichtung und Kit hierzu |
| WO2021075555A1 (ja) | 2019-10-18 | 2021-04-22 | 株式会社Ｅｐｉｇｅｎｅｒｏｎ | 標的核酸の検出方法、核酸結合分子の検出方法、及び核酸結合能の評価方法 |
| CN111197110A (zh) * | 2020-01-16 | 2020-05-26 | 浙江农林大学 | 用于检测猫泛白细胞减少症病毒的rpa-fld方法 |
| CN111518669A (zh) * | 2020-05-07 | 2020-08-11 | 安徽科技学院 | 一种核酸检测微流控芯片及其应用 |
| WO2021226754A1 (zh) * | 2020-05-09 | 2021-11-18 | 杭州梓晶生物有限公司 | 一种病毒重组酶-聚合酶扩增检测方法 |
| US20240279751A1 (en) | 2020-06-10 | 2024-08-22 | King Abdullah University Of Science And Technology | A rapid multiplex rpa based nanopore sequencing method for real-time detection and sequencing of multiple viral pathogens |
| CN111979303A (zh) * | 2020-08-11 | 2020-11-24 | 上海奕谱生物科技有限公司 | 一种核酸检测试剂盒、方法及其应用 |
| EP3995592A1 (en) | 2020-11-09 | 2022-05-11 | midge medical GmbH | Multimeric isothermal nucleic acid amplification methods for point-of-need diagnosis |
| WO2022078775A1 (en) | 2020-10-14 | 2022-04-21 | Midge Medical Gmbh | Isothermal nucleic acid amplification methods for point-of-need diagnosis |
| EP3985128A1 (en) | 2020-10-14 | 2022-04-20 | midge medical GmbH | Isothermal nucleic acid amplification methods for point-of-need diagnosis of emerging infectious diseases |
| CN112501262A (zh) * | 2020-12-15 | 2021-03-16 | 苏州点晶生物科技有限公司 | 一种基于双重多酶介导的核酸扩增检测方法及试剂 |
| CN112708662B (zh) * | 2020-12-28 | 2021-08-31 | 阅尔基因技术（苏州）有限公司 | 抑制生物dna样本中非目标区域的核苷酸组合物及其应用 |
| EP4053293A1 (en) | 2021-03-03 | 2022-09-07 | midge medical GmbH | Protected isothermal nucleic acid amplification (pina) methods for point-of-need diagnosis of emerging infectious diseases |
| CN114085891A (zh) * | 2021-11-23 | 2022-02-25 | 广州达安基因股份有限公司 | 基于重组酶聚合酶扩增技术的逆转录扩增系统和方法 |
| CN113981045B (zh) * | 2021-11-23 | 2025-09-16 | 广州达安基因股份有限公司 | 制备恒温扩增混合酶系的方法 |
| CN114262697B (zh) * | 2021-12-30 | 2022-12-13 | 南京巨匠生物科技有限公司 | 融合Bsu DNA聚合酶和Bsu DNA聚合酶突变体及其基因、质粒、基因工程菌 |
| CN116004773B (zh) * | 2022-09-30 | 2025-04-08 | 华南农业大学 | 一种线性置换等温扩增方法及其应用 |
| CN115747187B (zh) * | 2022-12-09 | 2023-06-20 | 厦门康基生物科技有限公司 | 一种重组酶UvsX及其表达基因和应用 |
| EP4477663A1 (en) | 2023-06-14 | 2024-12-18 | midge medical GmbH | Proteins for isothermal amplification |
| CN119534585B (zh) * | 2024-12-06 | 2025-11-28 | 安徽工业大学 | 用于检测微囊藻毒素mc-lr的ecl生物传感器 |
| CN119776321B (zh) * | 2025-02-05 | 2025-11-04 | 北洋酶(天津)生物科技有限公司 | UvsY蛋白突变体及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273881A (en) | 1990-05-07 | 1993-12-28 | Daikin Industries, Ltd. | Diagnostic applications of double D-loop formation |
| US5223414A (en) | 1990-05-07 | 1993-06-29 | Sri International | Process for nucleic acid hybridization and amplification |
| AU661505B2 (en) * | 1990-05-07 | 1995-07-27 | Tapestry Pharmaceuticals, Inc. | Diagnostic applications of double D-loop formation |
| EP0556330B1 (en) | 1990-11-09 | 2002-05-22 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Method of targeting dna |
| US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5705366A (en) * | 1994-09-15 | 1998-01-06 | Johnson & Johnson Clinical Diagnostics, Inc. | Coamplification of target nucleic acids using volume exclusion agent in reaction composition, test kit and test device useful therefor |
| US20040110167A1 (en) * | 1995-07-13 | 2004-06-10 | Gerdes John C. | Lateral flow system for nucleic acid detection |
| WO2001066688A1 (en) * | 2000-03-08 | 2001-09-13 | Imagene Technology, Inc. | Lateral flow pcr with amplicon concentration and detection |
| DE60226856D1 (de) | 2001-04-20 | 2008-07-10 | Penn State Res Found | Verfahren zur manipulation von nukleinsäuren |
| AU2002341898A2 (en) * | 2001-09-28 | 2003-04-07 | University Of Delaware | Polymorphism detection and separation |
| US7244562B2 (en) * | 2001-11-01 | 2007-07-17 | Gene Check, Inc. | RecA assisted detection of mutations, single nucleotide polymorphisms and specific sequences |
| AU2003215391B2 (en) * | 2002-02-21 | 2007-05-24 | Abbott Diagnostics Scarborough, Inc. | Recombinase Polymerase Amplification |
| WO2004007078A1 (en) * | 2002-07-12 | 2004-01-22 | British Biocell International Limited | Lateral flow assay device and method |
| AU2003272438B2 (en) * | 2002-09-20 | 2009-04-02 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
| EP1403379A1 (en) * | 2002-09-24 | 2004-03-31 | QIAGEN GmbH | Enhanced coamplification of nucleic acids |
| JP2008018820A (ja) * | 2006-07-12 | 2008-01-31 | Nsk Ltd | 衝撃吸収式ステアリングコラム装置 |
-
2005
- 2005-04-11 JP JP2007514201A patent/JP5026958B2/ja not_active Expired - Lifetime
- 2005-04-11 ES ES05741662T patent/ES2425354T3/es not_active Expired - Lifetime
- 2005-04-11 EP EP10180482.1A patent/EP2336361B1/en not_active Expired - Lifetime
- 2005-04-11 CA CA2569512A patent/CA2569512C/en not_active Expired - Lifetime
- 2005-04-11 ES ES10180482T patent/ES2718482T3/es not_active Expired - Lifetime
- 2005-04-11 EP EP19153024.5A patent/EP3540073B1/en not_active Expired - Lifetime
- 2005-04-11 EP EP21192246.3A patent/EP3985125A1/en active Pending
- 2005-04-11 AU AU2005250233A patent/AU2005250233B2/en not_active Expired
- 2005-04-11 WO PCT/IB2005/001560 patent/WO2005118853A2/en not_active Ceased
- 2005-04-11 EP EP05741662.0A patent/EP1759012B1/en not_active Expired - Lifetime
-
2008
- 2008-04-02 JP JP2008096623A patent/JP5089466B2/ja not_active Expired - Lifetime
-
2011
- 2011-03-01 JP JP2011044524A patent/JP2011103900A/ja active Pending
-
2013
- 2013-02-19 JP JP2013029664A patent/JP5856576B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP3540073A1 (en) | 2019-09-18 |
| EP1759012B1 (en) | 2013-05-22 |
| WO2005118853A3 (en) | 2006-06-15 |
| AU2005250233B2 (en) | 2011-03-17 |
| EP3540073B1 (en) | 2021-08-25 |
| EP2336361A2 (en) | 2011-06-22 |
| WO2005118853A2 (en) | 2005-12-15 |
| JP5856576B2 (ja) | 2016-02-10 |
| EP2336361A3 (en) | 2011-07-06 |
| JP5026958B2 (ja) | 2012-09-19 |
| JP2008188020A (ja) | 2008-08-21 |
| ES2718482T3 (es) | 2019-07-02 |
| JP5089466B2 (ja) | 2012-12-05 |
| JP2011103900A (ja) | 2011-06-02 |
| CA2569512A1 (en) | 2005-12-15 |
| ES2425354T3 (es) | 2013-10-14 |
| JP2008500831A (ja) | 2008-01-17 |
| AU2005250233A1 (en) | 2005-12-15 |
| JP2013102769A (ja) | 2013-05-30 |
| EP2336361B1 (en) | 2019-01-23 |
| EP3985125A1 (en) | 2022-04-20 |
| EP1759012A2 (en) | 2007-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10947584B2 (en) | Recombinase polymerase amplification | |
| CA2569512C (en) | Recombinase polymerase amplification | |
| US7666598B2 (en) | Recombinase polymerase amplification | |
| AU2013201222B2 (en) | Recombinase Polymerase Amplification | |
| CA3041478C (en) | Recombinase polymerase amplification | |
| AU2015203225B2 (en) | Recombinase Polymerase Amplification | |
| Class et al. | Patent application title: Recombinase Polymerase Amplification Inventors: Olaf Piepenburg (Essex, GB) Colin H. Williams (Waltham, MA, US) Niall A. Armes (Suffolk, GB) Derek L. Stemple (Hertfordshire, GB) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |